Which has better earnings & valuation, GRAL or MAZE?

Maze Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 43.48 -$408.35M -$9.75 N/A Maze Therapeutics $167.50M 8.77 -$131.12M -$2.52 N/A

Is GRAL or MAZE more profitable?

Maze Therapeutics has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -236.95% -15.88% -14.02% Maze Therapeutics N/A -34.94% -30.18%

Does the media favor GRAL or MAZE?

In the previous week, GRAIL had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 13 mentions for GRAIL and 12 mentions for Maze Therapeutics. GRAIL's average media sentiment score of 0.60 beat Maze Therapeutics' score of 0.57 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is COGT or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% Maze Therapeutics N/A -34.94% -30.18%

Does the media refer more to COGT or MAZE?

In the previous week, Maze Therapeutics had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Maze Therapeutics and 2 mentions for Cogent Biosciences. Maze Therapeutics' average media sentiment score of 0.57 beat Cogent Biosciences' score of 0.55 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MAZE or TVTX?

In the previous week, Maze Therapeutics had 10 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 2 mentions for Travere Therapeutics. Maze Therapeutics' average media sentiment score of 0.57 beat Travere Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MAZE or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -34.94% -30.18% Oruka Therapeutics N/A -21.65% -20.88%

Does the media refer more to MAZE or ORKA?

In the previous week, Maze Therapeutics had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 4 mentions for Oruka Therapeutics. Maze Therapeutics' average media sentiment score of 0.57 beat Oruka Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MAZE or CRSP?

In the previous week, Maze Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 7 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.75 beat Maze Therapeutics' score of 0.57 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maze Therapeutics (MAZE) Competitors

$26.43 -0.22 (-0.83%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$26.46 +0.02 (+0.09%)

As of 10/2/2026 07:30 PM Eastern

Compare

MAZE vs. GRAL, COGT, TVTX, ORKA, and CRSP

Should you buy Maze Therapeutics stock or one of its competitors? Maze Therapeutics's main competitors and comparable companies include GRAIL (GRAL), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), Oruka Therapeutics (ORKA), and CRISPR Therapeutics (CRSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Maze Therapeutics compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Maze Therapeutics has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Maze Therapeutics	N/A	-34.94%	-30.18%

In the previous week, GRAIL had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 13 mentions for GRAIL and 12 mentions for Maze Therapeutics. GRAIL's average media sentiment score of 0.60 beat Maze Therapeutics' score of 0.57 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRAIL currently has a consensus price target of $102.70, indicating a potential downside of 28.31%. Maze Therapeutics has a consensus price target of $63.40, indicating a potential upside of 139.88%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

GRAIL has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market.

Maze Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	43.48	-$408.35M	-$9.75	N/A
Maze Therapeutics	$167.50M	8.77	-$131.12M	-$2.52	N/A

Summary

Maze Therapeutics beats GRAIL on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Maze Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Maze Therapeutics	$167.50M	8.77	-$131.12M	-$2.52	N/A

In the previous week, Maze Therapeutics had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Maze Therapeutics and 2 mentions for Cogent Biosciences. Maze Therapeutics' average media sentiment score of 0.57 beat Cogent Biosciences' score of 0.55 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences presently has a consensus target price of $51.56, indicating a potential upside of 66.20%. Maze Therapeutics has a consensus target price of $63.40, indicating a potential upside of 139.88%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Maze Therapeutics' return on equity of -34.94% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Maze Therapeutics	N/A	-34.94%	-30.18%

Cogent Biosciences has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Summary

Maze Therapeutics beats Cogent Biosciences on 12 of the 13 factors compared between the two stocks.

How does Maze Therapeutics compare to Travere Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Travere Therapeutics has higher revenue and earnings than Maze Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.77	-$131.12M	-$2.52	N/A
Travere Therapeutics	$490.73M	10.94	-$25.55M	-$0.46	N/A

In the previous week, Maze Therapeutics had 10 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 2 mentions for Travere Therapeutics. Maze Therapeutics' average media sentiment score of 0.57 beat Travere Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics currently has a consensus target price of $63.40, suggesting a potential upside of 139.88%. Travere Therapeutics has a consensus target price of $69.50, suggesting a potential upside of 22.08%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Maze Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Maze Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Maze Therapeutics' return on equity of -34.94% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Maze Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

Maze Therapeutics beats Travere Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Oruka Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Maze Therapeutics presently has a consensus target price of $63.40, suggesting a potential upside of 139.88%. Oruka Therapeutics has a consensus target price of $128.91, suggesting a potential upside of 52.52%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Maze Therapeutics had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 4 mentions for Oruka Therapeutics. Maze Therapeutics' average media sentiment score of 0.57 beat Oruka Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.4% of Oruka Therapeutics shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oruka Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.77	-$131.12M	-$2.52	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Maze Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market.

Oruka Therapeutics' return on equity of -21.65% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Summary

Maze Therapeutics beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to CRISPR Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Maze Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.77	-$131.12M	-$2.52	N/A
CRISPR Therapeutics	$11M	487.24	-$581.60M	-$4.76	N/A

Maze Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Maze Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Maze Therapeutics currently has a consensus target price of $63.40, indicating a potential upside of 139.88%. CRISPR Therapeutics has a consensus target price of $67.94, indicating a potential upside of 22.57%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Maze Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

In the previous week, Maze Therapeutics had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 12 mentions for Maze Therapeutics and 7 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.75 beat Maze Therapeutics' score of 0.57 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maze Therapeutics beats CRISPR Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.48B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-10.49	12.93	273.77	26.04
Price / Sales	8.77	1,292.30	607.64	84.84
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	3.58	16.63	10.92	6.30
Net Income	-$131.12M	-$22.67M	$3.50B	$361.43M
7 Day Performance	1.46%	-3.10%	-2.07%	-1.67%
1 Month Performance	2.16%	-10.70%	-6.21%	-4.51%
1 Year Performance	-2.51%	19.46%	7.45%	2.03%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	2.6939 of 5 stars	$26.43 -0.8%	$63.40 +139.9%	-0.3%	$1.48B	$167.50M	N/A	141	News Coverage Insider Trade
GRAL GRAIL	1.0444 of 5 stars	$126.89 +1.3%	$78.60 -38.1%	+121.3%	$5.67B	$165.26M	N/A	910	Analyst Forecast Gap Up
COGT Cogent Biosciences	2.3259 of 5 stars	$32.31 +2.8%	$51.56 +59.6%	+110.3%	$5.61B	N/A	N/A	258	News Coverage
TVTX Travere Therapeutics	1.6689 of 5 stars	$59.44 -1.9%	$69.50 +16.9%	+135.1%	$5.60B	$591.33M	N/A	497
ORKA Oruka Therapeutics	2.2573 of 5 stars	$84.46 -1.2%	$128.91 +52.6%	+340.7%	$5.59B	N/A	N/A	68	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. GRAL, COGT, TVTX, ORKA, and CRSP

How does Maze Therapeutics compare to GRAIL?

Summary

How does Maze Therapeutics compare to Cogent Biosciences?

Summary

How does Maze Therapeutics compare to Travere Therapeutics?

Summary

How does Maze Therapeutics compare to Oruka Therapeutics?

Summary

How does Maze Therapeutics compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. GRAL, COGT, TVTX, ORKA, and CRSP

How does Maze Therapeutics compare to GRAIL?

Is GRAL or MAZE more profitable?

Does the media favor GRAL or MAZE?

Do analysts prefer GRAL or MAZE?

Which has more volatility & risk, GRAL or MAZE?

Which has better earnings & valuation, GRAL or MAZE?

Summary

How does Maze Therapeutics compare to Cogent Biosciences?

Which has higher earnings and valuation, COGT or MAZE?

Does the media refer more to COGT or MAZE?

Do analysts rate COGT or MAZE?

Is COGT or MAZE more profitable?

Which has more volatility and risk, COGT or MAZE?

Summary

How does Maze Therapeutics compare to Travere Therapeutics?

Which has stronger valuation & earnings, MAZE or TVTX?

Does the media favor MAZE or TVTX?

Do analysts rate MAZE or TVTX?

Is MAZE or TVTX more profitable?

Which has more volatility and risk, MAZE or TVTX?

Summary

How does Maze Therapeutics compare to Oruka Therapeutics?

Do analysts rate MAZE or ORKA?

Does the media refer more to MAZE or ORKA?

Do institutionals and insiders hold more shares of MAZE or ORKA?

Which has better valuation and earnings, MAZE or ORKA?

Which has more risk & volatility, MAZE or ORKA?

Is MAZE or ORKA more profitable?

Summary

How does Maze Therapeutics compare to CRISPR Therapeutics?

Which has higher earnings and valuation, MAZE or CRSP?

Which has more risk and volatility, MAZE or CRSP?

Do institutionals & insiders have more ownership in MAZE or CRSP?

Is MAZE or CRSP more profitable?

Do analysts rate MAZE or CRSP?

Does the media refer more to MAZE or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools